Emerging Molecules
CJC-1295 with DAC raised GH and IGF-I for days in healthy adults
Teichman 2006 and Ionescu 2006 describe the long-acting, Drug Affinity Complex form. “No DAC” is a different pharmacokinetic product.
CJC-1295 is a growth hormone-releasing hormone analogue built to last longer than native GHRH. In the version that carries a Drug Affinity Complex, the peptide binds albumin and stays in circulation. Teichman and colleagues gave that long-acting analogue to healthy adults and reported prolonged stimulation of growth hormone and IGF-I, measured over days rather than minutes. Ionescu and Frohman then showed that pulsatile GH secretion persisted during that continuous stimulation. The axis was being driven, not flattened into a single square wave.
The name collision on catalogs
Research listings split “CJC-1295 with DAC” from “CJC-1295 no DAC,” and they sometimes equate the no-DAC material with modified GRF 1-29. Those are not interchangeable with the Teichman injections. A short-acting GHRH analogue given several times a day is a different exposure from an albumin-binding analogue given infrequently. Quoting the 2006 IGF-I curves next to a no-DAC vial misstates the paper.
What the phase 1 did not claim
These studies characterized hormone kinetics in adults. They were not body-composition trials, not athletic-performance trials, and not a safety file for multi-month unsupervised use. A later review of secretagogues by Sigalos and Pastuszak is a better doorway into the wider safety discussion than any single pharmacokinetic figure.